INTRODUCTION: CD8+ lymphocytes can suppress HIV replication without killing the infected cells. This CD8+ cell noncytotoxic anti-HIV response (CNAR) is associated with a beneficial clinical course. MATERIALS AND METHODS: In this longitudinal study of 16 participants in the Options Project at UCSF, we measured the ability of CD8+ lymphocytes to suppress HIV replication in CD4+ cells during primary HIV infection, early antiretroviral therapy, and after treatment. RESULTS AND DISCUSSION: CD8+ lymphocytes from subjects with untreated primary HIV-1 infection strongly suppressed HIV replication. Initiation of antiretroviral therapy during primary HIV-1 infection caused a marked decline in this CNAR. CD8+ cells from these subjects regained anti-HIV activity when early therapy was discontinued. The timing of the appearance of CD8+ cell anti-HIV activity directly correlated with the emergence of detectable virus levels. Maximal CNAR activity coincided with a decay in the kinetics of HIV replication. In addition, peak viral loads during treatment interruption were lower than pre-treatment virus levels (median reduction = 0.8 logs, p = 0.005) and CD4+ T cell counts were maintained for a 24-week period of follow-up. CONCLUSION: These results suggest that CNAR plays an important role in suppressing HIV replication in the setting of antiretroviral treatment interruption in HIV-infected individuals.
INTRODUCTION:CD8+ lymphocytes can suppress HIV replication without killing the infected cells. This CD8+ cell noncytotoxic anti-HIV response (CNAR) is associated with a beneficial clinical course. MATERIALS AND METHODS: In this longitudinal study of 16 participants in the Options Project at UCSF, we measured the ability of CD8+ lymphocytes to suppress HIV replication in CD4+ cells during primary HIV infection, early antiretroviral therapy, and after treatment. RESULTS AND DISCUSSION: CD8+ lymphocytes from subjects with untreated primary HIV-1 infection strongly suppressed HIV replication. Initiation of antiretroviral therapy during primary HIV-1 infection caused a marked decline in this CNAR. CD8+ cells from these subjects regained anti-HIV activity when early therapy was discontinued. The timing of the appearance of CD8+ cell anti-HIV activity directly correlated with the emergence of detectable virus levels. Maximal CNAR activity coincided with a decay in the kinetics of HIV replication. In addition, peak viral loads during treatment interruption were lower than pre-treatment virus levels (median reduction = 0.8 logs, p = 0.005) and CD4+ T cell counts were maintained for a 24-week period of follow-up. CONCLUSION: These results suggest that CNAR plays an important role in suppressing HIV replication in the setting of antiretroviral treatment interruption in HIV-infected individuals.
Authors: Kyle R Bonneau; Sharon Ng; Hillary Foster; Kelly B Choi; Ben Berkhout; Arnold Rabson; Carl E Mackewicz; Jay A Levy Journal: Virology Date: 2007-12-20 Impact factor: 3.616
Authors: Frederick M Hecht; Michael P Busch; Bhupat Rawal; Marcy Webb; Eric Rosenberg; Melinda Swanson; Margaret Chesney; Jennifer Anderson; Jay Levy; James O Kahn Journal: AIDS Date: 2002-05-24 Impact factor: 4.177
Authors: M K Elkins; E Vittinghoff; S E Baranzini; F M Hecht; U Sriram; M P Busch; J A Levy; J R Oksenberg Journal: Genes Immun Date: 2005-02 Impact factor: 2.676
Authors: Carolyn A Robinson; Terri D Lyddon; Hwi Min Gil; David T Evans; Yury V Kuzmichev; Jonathan Richard; Andrés Finzi; Sarah Welbourn; Lynn Rasmussen; N Miranda Nebane; Vandana V Gupta; Sam Ananthan; Zhaohui Cai; Elizabeth R Wonderlich; Corinne E Augelli-Szafran; Robert Bostwick; Roger G Ptak; Susan M Schader; Marc C Johnson Journal: Viruses Date: 2022-04-15 Impact factor: 5.818
Authors: Yihong Li; Deepak Saxena; Zhou Chen; Gaoxia Liu; Willam R Abrams; Joan A Phelan; Robert G Norman; Gene S Fisch; Patricia M Corby; Floyd Dewhirst; Bruce J Paster; Alexis S Kokaras; Daniel Malamud Journal: J Clin Microbiol Date: 2014-02-12 Impact factor: 5.948
Authors: M Scott Killian; Fernando Teque; Robert L Walker; Paul S Meltzer; J Keith Killian Journal: J Interferon Cytokine Res Date: 2013-02-12 Impact factor: 2.607
Authors: Joshua T Schiffer; Dave A Swan; Pavitra Roychoudhury; Jennifer M Lund; Martin Prlic; Jia Zhu; Anna Wald; Lawrence Corey Journal: J Immunol Date: 2018-07-25 Impact factor: 5.422